pmlive.com
Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing durable treatment options.
Adults with moderately to severely active Crohn’s disease, people who have failed prior biologics, clinicians prescribing IBD biologics, and researchers following IL-23-targeted therapies.
What To Know
Two-year open-label extension (VIVID-2) data for Omvoh (mirikizumab-mrkz) in adults with moderately to severely active Crohn’s disease were reported.
The article summarizes that many patients maintained clinical and endoscopic remission or response with two years of continuous treatment, including people with prior biologic failure, and notes regulatory progress in Europe. The findings were presented at Crohn’s and Colitis Congress and build on the phase 3 VIVID-1 results that supported FDA approval.
This is a report of longer-term outcomes from an open-label extension following phase 3 studies — not a new randomized trial. The results described are proportions of patients maintaining or achieving clinical and endoscopic remission or response over two years on continued mirikizumab treatment.
The article does not provide detailed safety data, patient-level outcomes, or statistical analyses here. If you use or are considering biologic therapy: these findings are relevant as evidence for durability of effect with mirikizumab, especially for some patients who previously failed other biologics.
Discuss specifics, including benefits and risks, with your treating clinician to understand whether this therapy and the evidence apply to your situation.
This article summarizes company-reported results from an open-label extension presented at a conference; open-label extensions lack a control arm and can be subject to selection or attrition bias. The piece does not include full safety or detailed statistical information. Regulatory review in Europe is ongoing; FDA approval in the US for Crohn’s disease was already mentioned.
